-- Data Reinforce Breadth of Cell Therapy Portfolio and Commitment
to Continued Innovation for People with Advanced Cancers --
Company Website:
http://www.gilead.com
FOSTER CITY, Calif. -- (Business Wire)
Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from its
oncology and cell therapy research programs will be presented at the 60th
American Society of Hematology (ASH) Annual Meeting & Exposition, in San
Diego from December 1 – 4, 2018. Twelve abstracts will be presented,
including data highlighting Gilead’s broad cell therapy pipeline in
hematologic malignancies and solid tumors.
Notable data to be presented at the meeting include new analyses from
the ZUMA chimeric antigen receptor T (CAR T) cell therapy development
program, including long-term data from the Yescarta® (axicabtagene
ciloleucel) ZUMA-1 trial showing efficacy and safety results with a
minimum follow-up of two years in certain patients with refractory large
B-cell lymphoma, and updates to the ZUMA-3 study evaluating
investigational KTE-X19 (formerly KTE-C19) in adult patients with
relapsed or refractory acute lymphoblastic leukemia (ALL). Data from two
trials as part of Cooperative Research and Development Agreements
(CRADAs) between the Experimental Transplantation and Immunology Branch
(ETIB) of the National Cancer Institute (NCI) Center for Cancer Research
and Kite, a Gilead Company, to further the research and clinical
development of cell therapies, including a T cell receptor (TCR) product
candidate for the treatment of HPV-associated solid tumors, will also be
presented in oral sessions.
“At Gilead and Kite, we are proud to be leading the field of cell
therapy with our research and development efforts on behalf of
patients,” said Alessandro Riva, MD, Gilead’s Executive Vice President,
Oncology Therapeutics & Head, Cell Therapy. “We look forward to sharing
data at ASH that highlight the long-term treatment observed with
Yescarta in refractory large B-cell lymphoma, as well as the potential
of our pipeline of investigational cell therapies in treating other
advanced cancers.”
Yescarta was the first CAR T cell therapy to be approved by the U.S.
Food and Drug Administration (FDA) for the treatment of adult patients
with relapsed or refractory large B-cell lymphoma after two or more
lines of systemic therapy, including diffuse large B-cell lymphoma
(DLBCL) not otherwise specified, primary mediastinal large B-cell
lymphoma, high grade B-cell lymphoma and DLBCL arising from follicular
lymphoma. Yescarta is not indicated for the treatment of patients with
primary central nervous system lymphoma. The Yescarta U.S. Prescribing
Information has a BOXED WARNING for the risks of cytokine release
syndrome and neurologic toxicities; see below for Important Safety
Information.
Key presentations at ASH will include:
|
|
|
Area of Focus, Presentation Number and Date/Time (PST) |
| Abstract Title |
Cell Therapy Presentations |
Large B-Cell Lymphoma
Abstract #2967 (Poster)
Sunday, Dec 2 (6:00-8:00 pm) |
|
2-Year Follow-Up and High-Risk Subset Analysis of ZUMA-1, the
Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients With
Refractory Large B Cell Lymphoma
|
Solid Tumors
Abstract #492 (Oral)
Sunday, Dec 2 (5:45 pm) |
|
Regression of Epithelial Cancers Following T Cell Receptor Gene
Therapy Targeting Human Papillomavirus-16 E7
|
Large B-Cell Lymphoma
Abstract #678 (Oral)
Monday, Dec 3 (11:45 am) |
|
Analysis of CAR-T and Immune Cells within the Tumor
Micro-Environment of Diffuse Large B-Cell Lymphoma Post CAR-T
Treatment By Multiplex Immunofluorescence
|
Large B-Cell Lymphoma
Abstract #697 (Oral)
Monday, Dec 3 (10:30 am) |
|
Low Levels of Neurologic Toxicity with Retained Anti-Lymphoma
Activity in a Phase I Clinical Trial of T Cells Expressing a Novel
Anti-CD19 CAR
|
ALL
Abstract #897 (Oral)
Monday, Dec 3 (5:00 pm) |
|
Updated Phase 1 Results of ZUMA-3: KTE-C19, an Anti-CD19 Chimeric
Antigen Receptor T Cell Therapy, in Adult Patients With
Relapsed/Refractory Acute Lymphoblastic Leukemia
|
Large B-Cell Lymphoma
Abstract #4192 (Poster)
Monday, Dec 3 (6:00-8:00 pm) |
|
End of Phase 1 Results From ZUMA-6: Axicabtagene Ciloleucel
(Axi-Cel) in Combination With Atezolizumab for the Treatment of
Patients With Refractory Diffuse Large B Cell Lymphoma
|
Large B-Cell Lymphoma
Abstract #4779 (Poster)
Monday, Dec 3 (6:00-8:00 pm) |
|
Cost-Effectiveness of Axicabtagene Ciloleucel for Relapsed or
Refractory Diffuse Large B-Cell Lymphoma in Italy
|
Large B-Cell Lymphoma
Abstract #4795 (Poster)
Monday, Dec 3 (6:00-8:00 pm) |
|
Comparing Survival for Different CAR Ts: Need for Addressing Bias
Due to Differences in the Pre-Infusion Period
|
Additional Key Hematology Presentations |
CLL/FL
Abstract #2302 (Poster)
Saturday, Dec 1 (6:15-8:15 pm) |
|
Real-World Clinical Management of Patients Treated with Idelalisib
in France: A Study of 529 Cases of Chronic Lymphocytic Leukemia
(CLL) and Follicular Lymphoma (FL)
|
CLL
Abstract #3135 (Poster)
Sunday, Dec 2 (6:00-8:00 pm) |
|
Updated Preliminary Results of a Phase 1b Dose Escalation and Dose
Expansion Study of Tirabrutinib Alone or in Combination with
Idelalisib or Entospletinib in Patients with Previously Treated
Chronic Lymphocytic Leukemia
|
CLL/FL
Abstract #3149 (Poster)
Sunday, Dec 2 (6:00-8:00 pm) |
|
Survival Outcomes Following Idelalisib Interruption in the
Treatment of Relapsed or Refractory Indolent Non-Hodgkin's
Lymphoma and Chronic Lymphocytic Leukemia
|
CLL
Abstract #4428 (Poster)
Monday, Dec 3 (6:00-8:00 pm) |
|
Results From a Prospective Real World Study Show Strong Efficacy of
Idelalisib in CLL, Including High-Risk CLL, and Provide Evidence
That PJP Prophylaxis Positively Impacts On Overall Survival
|
|
| |
For more information, including a complete list of abstract titles at
the meeting, please visit: http://www.hematology.org/Annual-Meeting/3225.aspx.
Zydelig® (idelalisib) is approved in the U.S. for the
treatment of relapsed follicular lymphoma (FL) or small lymphocytic
lymphoma (SLL) in patients who have received at least two prior systemic
therapies, and relapsed chronic lymphocytic leukemia (CLL), in
combination with rituximab, in patients for whom rituximab alone would
be considered appropriate due to other comorbidities. Accelerated
approval was granted for FL based on overall response rate. An
improvement in patient survival or disease-related symptoms has not been
established. Zydelig is not indicated or recommended for first-line
treatment of any patient or in combination with bendamustine and/or
rituximab for the treatment of FL. The Zydelig U.S. Prescribing
Information has a BOXED WARNING for the risks of fatal and serious
toxicities: hepatic, severe diarrhea, colitis, pneumonitis, infections,
and intestinal perforation; see below for Important Safety Information.
KTE-X19, the combination of axicabtagene ciloleucel with atezolizumab,
and tirabrutinib alone or in combination with idelalisib or
entospletinib are investigational and are not approved globally; the
safety and efficacy have not been established.
U.S. Important Safety Information for Yescarta
BOXED WARNING:CYTOKINE RELEASE SYNDROME AND NEUROLOGIC
TOXICITIES
- Cytokine Release Syndrome (CRS), including fatal or
life-threatening reactions, occurred in patients receiving Yescarta®.
Do not administer Yescarta® to patients with
active infection or inflammatory disorders. Treat severe or
life-threatening CRS with tocilizumab or tocilizumab and
corticosteroids.
- Neurologic toxicities, including fatal or life-threatening
reactions, occurred in patients receiving Yescarta®,
including concurrently with CRS or after CRS resolution. Monitor for
neurologic toxicities after treatment with Yescarta®.
Provide supportive care and/or corticosteroids as needed.
- Yescarta® is available only through a
restricted program under a Risk Evaluation and Mitigation Strategy
(REMS) called the Yescarta® REMS.
CYTOKINE RELEASE SYNDROME (CRS): CRS occurred in 94% of patients,
including 13% with ≥ Grade 3. Among patients who died after receiving
Yescarta®, 4 had ongoing CRS at death. The median time to
onset was 2 days (range: 1-12 days) and median duration was 7 days
(range: 2-58 days). Key manifestations include fever (78%), hypotension
(41%), tachycardia (28%), hypoxia (22%), and chills (20%). Serious
events that may be associated with CRS include cardiac arrhythmias
(including atrial fibrillation and ventricular tachycardia), cardiac
arrest, cardiac failure, renal insufficiency, capillary leak syndrome,
hypotension, hypoxia, and hemophagocytic lymphohistiocytosis/macrophage
activation syndrome. Ensure that 2 doses of tocilizumab are
available prior to infusion of Yescarta®. Monitor patients at
least daily for 7 days at the certified healthcare facility following
infusion for signs and symptoms of CRS. Monitor patients for signs or
symptoms of CRS for 4 weeks after infusion. Counsel patients to seek
immediate medical attention should signs or symptoms of CRS occur at any
time. At the first sign of CRS, institute treatment with supportive
care, tocilizumab or tocilizumab and corticosteroids as indicated.
NEUROLOGIC TOXICITIES: Neurologic toxicities occurred in 87% of
patients. Ninety-eight percent of all neurologic toxicities occurred
within the first 8 weeks, with a median time to onset of 4 days (range:
1-43 days) and a median duration of 17 days. Grade 3 or higher occurred
in 31% of patients. The most common neurologic toxicities included
encephalopathy (57%), headache (44%), tremor (31%), dizziness (21%),
aphasia (18%), delirium (17%), insomnia (9%) and anxiety (9%). Prolonged
encephalopathy lasting up to 173 days was noted. Serious events
including leukoencephalopathy and seizures occurred with Yescarta®.
Fatal and serious cases of cerebral edema have occurred in patients
treated with Yescarta®. Monitor patients at least daily for 7
days at the certified healthcare facility following infusion for signs
and symptoms of neurologic toxicities. Monitor patients for signs or
symptoms of neurologic toxicities for 4 weeks after infusion and treat
promptly.
YESCARTA® REMS: Because of the risk of
CRS and neurologic toxicities, Yescarta® is available only
through a restricted program under a Risk Evaluation and Mitigation
Strategy (REMS) called the Yescarta® REMS. The required
components of the Yescarta® REMS are: Healthcare facilities
that dispense and administer Yescarta® must be enrolled and
comply with the REMS requirements. Certified healthcare facilities must
have on-site, immediate access to tocilizumab, and ensure that a minimum
of 2 doses of tocilizumab are available for each patient for infusion
within 2 hours after Yescarta® infusion, if needed for
treatment of CRS. Certified healthcare facilities must ensure that
healthcare providers who prescribe, dispense or administer Yescarta®
are trained about the management of CRS and neurologic toxicities.
Further information is available at www.YESCARTAREMS.com
or 1-844-454-KITE (5483).
HYPERSENSITIVITY REACTIONS: Allergic reactions may occur. Serious
hypersensitivity reactions including anaphylaxis may be due to dimethyl
sulfoxide (DMSO) or residual gentamicin in Yescarta®.
SERIOUS INFECTIONS: Severe or life-threatening infections
occurred. Infections (all grades) occurred in 38% of patients, and in
23% with ≥ Grade 3. Grade 3 or higher infections with an unspecified
pathogen occurred in 16% of patients, bacterial infections in 9%, and
viral infections in 4%. Yescarta® should not be administered
to patients with clinically significant active systemic infections.
Monitor patients for signs and symptoms of infection before and after
Yescarta® infusion and treat appropriately. Administer
prophylactic anti-microbials according to local guidelines. Febrile
neutropenia was observed in 36% of patients and may be concurrent with
CRS. In the event of febrile neutropenia, evaluate for infection and
manage with broad spectrum antibiotics, fluids and other supportive care
as medically indicated. Hepatitis B virus (HBV) reactivation, in some
cases resulting in fulminant hepatitis, hepatic failure and death, can
occur in patients treated with drugs directed against B cells. Perform
screening for HBV, HCV, and HIV in accordance with clinical guidelines
before collection of cells for manufacturing.
PROLONGED CYTOPENIAS: Patients may exhibit cytopenias for several
weeks following lymphodepleting chemotherapy and Yescarta®
infusion. Grade 3 or higher cytopenias not resolved by Day 30 following
Yescarta® infusion occurred in 28% of patients and included
thrombocytopenia (18%), neutropenia (15%), and anemia (3%). Monitor
blood counts after Yescarta® infusion.
HYPOGAMMAGLOBULINEMIA: B-cell aplasia and hypogammaglobulinemia
can occur. Hypogammaglobulinemia occurred in 15% of patients. Monitor
immunoglobulin levels after treatment and manage using infection
precautions, antibiotic prophylaxis and immunoglobulin replacement. The
safety of immunization with live viral vaccines during or following
Yescarta® treatment has not been studied. Vaccination with
live virus vaccines is not recommended for at least 6 weeks prior to the
start of lymphodepleting chemotherapy, during Yescarta®
treatment, and until immune recovery following treatment.
SECONDARY MALIGNANCIES: Patients may develop secondary
malignancies. Monitor life-long for secondary malignancies. In the event
that a secondary malignancy occurs, contact Kite at 1-844-454-KITE
(5483) to obtain instructions on patient samples to collect for testing.
EFFECTS ON ABILITY TO DRIVE AND USE MACHINES: Due to the
potential for neurologic events, including altered mental status or
seizures, patients are at risk for altered or decreased consciousness or
coordination in the 8 weeks following Yescarta® infusion.
Advise patients to refrain from driving and engaging in hazardous
occupations or activities, such as operating heavy or potentially
dangerous machinery, during this initial period.
ADVERSE REACTIONS: The most common adverse reactions (incidence ≥
20%) include CRS, fever, hypotension, encephalopathy, tachycardia,
fatigue, headache, decreased appetite, chills, diarrhea, febrile
neutropenia, infections-pathogen unspecified, nausea, hypoxia, tremor,
cough, vomiting, dizziness, constipation, and cardiac arrhythmias.
Please see accompanying full Prescribing Information, including BOXED
WARNING and Medication Guide.
U.S. Important Safety Information for Zydelig
BOXED WARNING: FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE
DIARRHEA, COLITIS, PNEUMONITIS, INFECTIONS, AND INTESTINAL PERFORATION
- Fatal and/or serious hepatotoxicity occurred in 16% to 18% of
Zydelig®-treated patients. Monitor hepatic function
prior to and during treatment. Interrupt and then reduce or
discontinue Zydelig®.
- Fatal and/or serious and severe diarrhea or colitis occurred in 14%
to 20% of Zydelig-treated patients. Monitor for the development of
severe diarrhea or colitis. Interrupt and then reduce or discontinue
Zydelig®.
- Fatal and/or serious pneumonitis occurred in 4% of Zydelig®-treated
patients. Monitor for pulmonary symptoms and bilateral interstitial
infiltrates. Interrupt or discontinue Zydelig®.
- Fatal and/or serious infections occurred in 21% to 48% of
Zydelig-treated patients. Monitor for signs and symptoms of infection.
Interrupt Zydelig® if infection is suspected.
- Fatal and serious intestinal perforation can occur in
Zydelig-treated patients. Discontinue Zydelig® if
intestinal perforation is suspected.
Contraindications
- History of serious allergic reactions, including anaphylaxis
and toxic epidermal necrolysis (TEN).
Warnings and Precautions
- Hepatotoxicity: Fatal and/or serious hepatotoxicity occurred in
18% of patients treated with Zydelig® monotherapy and 16%
of patients treated with Zydelig® in combination with
rituximab or with unapproved combination therapies. Findings were
generally observed within the first 12 weeks of treatment and reversed
with dose interruption. Upon rechallenge at a lower dose, ALT/AST
elevations recurred in 26% of patients. In all patients, monitor
ALT/AST every 2 weeks for the first 3 months, every 4 weeks for the
next 3 months, and every 1 to 3 months thereafter. If ALT/AST is >3x
upper limit of normal (ULN), monitor for liver toxicity weekly. If
ALT/AST is >5x ULN, withhold Zydelig® and monitor
ALT/AST and total bilirubin weekly until resolved. Discontinue ZYDELIG
for recurrent hepatotoxicity. Avoid concurrent use with other
hepatotoxic drugs.
- Severe diarrhea or colitis: Severe diarrhea or colitis (Grade
≥3) occurred in 14% of patients treated with Zydelig®
monotherapy and 20% of patients treated with Zydelig® in
combination with rituximab or with unapproved combination therapies.
Grade 3+ diarrhea can occur at any time and responds poorly to
antimotility agents. Avoid concurrent use with other drugs that cause
diarrhea.
- Pneumonitis: Fatal and serious pneumonitis occurred in 4% of
patients treated with Zydelig® compared to 1% on the
comparator arms in randomized clinical trials of combination
therapies. Time to onset of pneumonitis ranged from <1 to 15 months.
Clinical manifestations included interstitial infiltrates and
organizing pneumonia. Monitor patients on Zydelig® for
pulmonary symptoms. In patients presenting with pulmonary symptoms
such as cough, dyspnea, hypoxia, interstitial infiltrates on
radiologic exam, or oxygen saturation decline by ≥5%, interrupt
ZYDELIG until the etiology has been determined. If symptomatic
pneumonitis or organizing pneumonia is diagnosed, initiate appropriate
treatment with corticosteroids and permanently discontinue Zydelig®.
- Infections: Fatal and/or serious infections occurred in 21% of
patients treated with Zydelig® monotherapy and 48% of
patients treated with Zydelig® in combination with
rituximab or with unapproved combination therapies. The most common
infections were pneumonia, sepsis, and febrile neutropenia. Treat
infections prior to initiation of Zydelig® therapy and
interrupt Zydelig® for Grade 3 or higher infection. Serious
or fatal Pneumocystis jirovecii pneumonia (PJP) or
cytomegalovirus (CMV) occurred in <1% of patients treated with Zydelig®.
Provide PJP prophylaxis during treatment with ZYDELIG. Interrupt
Zydelig® in patients with suspected PJP infection of any
grade, and permanently discontinue Zydelig® if PJP
infection of any grade is confirmed. Regular clinical and laboratory
monitoring for CMV infection is recommended in patients with a history
of CMV infection or positive CMV serology at the start of treatment
with Zydelig®. Interrupt Zydelig in the setting of positive
CMV PCR or antigen test until the viremia has resolved. If Zydelig is
subsequently resumed, patients should be monitored (by PCR or antigen
test) for CMV reactivation at least monthly.
- Intestinal perforation: Advise patients to promptly report any
new or worsening abdominal pain, chills, fever, nausea, or vomiting.
- Severe cutaneous reactions: Fatal cases of Stevens-Johnson
syndrome (SJS) andtoxic epidermal necrolysis (TEN) have
occurred. If suspected, interrupt Zydelig® until the
etiology of the reaction has been determined. If SJS or TEN is
confirmed, discontinue Zydelig®. Other severe or
life-threatening (Grade ≥3) cutaneous reactions have been reported.
Monitor patients for the development of severe cutaneous reactions and
discontinue Zydelig®.
- Anaphylaxis: Serious allergic reactions, including anaphylaxis,
have been reported. Discontinue Zydelig® permanently and
institute appropriate supportive measures if a reaction occurs.
- Neutropenia: Treatment-emergent Grade 3-4 neutropenia occurred
in 25% of patients treated with monotherapy and 58% of patients
treated with Zydelig® in combination with rituximab or with
unapproved combination therapies. Monitor blood counts at least every
2 weeks for the first 6 months, and at least weekly in patients while
neutrophil counts are less than 1.0 Gi/L.
- Embryo-fetal toxicity: Zydelig® may cause fetal
harm. Women who are or become pregnant while taking Zydelig®
should be apprised of the potential hazard to the fetus. Advise women
to avoid pregnancy while taking Zydelig® and to use
effective contraception during and at least 1 month after treatment
with Zydelig®.
Adverse Reactions
- Most common adverse reactions in patients treated with Zydelig®
in combination trials (incidence ≥30%, all grades) were diarrhea,
pneumonia, pyrexia, fatigue, rash, cough, and nausea; and in the
monotherapy trial (incidence ≥20%, all grades) were diarrhea, fatigue,
nausea, cough, pyrexia, abdominal pain, pneumonia, and rash.
- Most frequent serious adverse reactions (SAR) in clinical
studies in combination with rituximab werepneumonia (23%),
diarrhea (10%), pyrexia (9%), sepsis (8%) and febrile neutropenia
(5%); SAR were reported in 59% of patients, and 17% discontinued
therapy due to adverse reactions. Most frequent SAR in clinical
studies when used alone were pneumonia (15%), diarrhea (11%), and
pyrexia (9%); SAR were reported in 50% of patients, and 53%
discontinued due to adverse reactions.
- Most common lab abnormalities include neutropenia, ALT
elevations, and AST elevations.
Drug Interactions
- CYP3A inducers: Avoid coadministration with strong CYP3A
inducers.
- CYP3A inhibitors: Avoid coadministration with strong CYP3A
inhibitors. If unable to use alternative drugs, monitor patients more
frequently for Zydelig® adverse reactions.
- CYP3A substrates: Avoid coadministration with sensitive CYP3A
substrates.
Dosage and Administration
- Adult starting dose: One 150 mg tablet twice daily, swallowed
whole with or without food. Continue treatment until disease
progression or unacceptable toxicity. The safe dosing regimen for
patients who require treatment longer than several months is unknown.
- Dose modification: Consult the Zydelig® full
Prescribing Information for dose modification and monitoring
recommendations for the following specific toxicities: pneumonitis,
ALT/AST elevations, bilirubin elevations, diarrhea, neutropenia,
thrombocytopenia, and infections. For other severe or life-threatening
toxicities, withhold Zydelig® until toxicity is resolved
and reduce the dose to 100 mg twice daily upon resuming treatment. If
severe or life-threatening toxicities recur upon rechallenge, Zydelig®
should be permanently discontinued.
About Kite
Kite, a Gilead Company, is a biopharmaceutical company based in Santa
Monica, California. Kite is engaged in the development of innovative
cancer immunotherapies. The company is focused on chimeric antigen
receptor and T cell receptor engineered cell therapies. For more
information on Kite, please visit www.kitepharma.com.
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that
discovers, develops and commercializes innovative medicines in areas of
unmet medical need. The company strives to transform and simplify care
for people with life-threatening illnesses around the world. Gilead has
operations in more than 35 countries worldwide, with headquarters
in Foster City, California. For more information on Gilead Sciences,
please visit the company’s website at www.gilead.com.
Forward-Looking Statement
This press release includes forward-looking statements, within the
meaning of the Private Securities Litigation Reform Act of 1995 that are
subject to risks, uncertainties and other factors, including the
possibility of unfavorable results from ongoing and additional clinical
trials involving Yescarta and Zydelig. All statements other than
statements of historical fact are statements that could be deemed
forward-looking statements. These risks, uncertainties and other factors
could cause actual results to differ materially from those referred to
in the forward-looking statements. The reader is cautioned not to rely
on these forward-looking statements. These and other risks are described
in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter
ended June 30, 2018, as filed with the U.S. Securities and Exchange
Commission. All forward-looking statements are based on information
currently available to Gilead and Kite, and Gilead and Kite assume no
obligation to update any such forward-looking statements.
U.S. Prescribing Information for Yescarta, including BOXED WARNING,
is available at www.kitepharma.com
and www.gilead.com.
U.S. Prescribing Information for Zydelig, including BOXED WARNING,
is available at www.gilead.com.
Yescarta, Axi-Cel and Zydelig are registered trademarks of Gilead
Sciences, Inc., or its related companies.
For more information on Kite, please visit the company’s website at www.kitepharma.com.
Learn more about Gilead at www.gilead.com,
follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs
at 1-800-GILEAD-5 or 1-650-574-3000.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181101005606/en/
Contacts:
Gilead Sciences, Inc.
Investors
Sung Lee, 650-524-7792
or
Media
Nathan
Kaiser, 650-522-1853
Source: Gilead Sciences, Inc.
© 2024 Canjex Publishing Ltd. All rights reserved.